ALX Oncology Initiates Phase 1 Clinical Trial for Promising EGFR-Targeted ADC, ALX2004, in Solid Tumor Treatment
ALX Oncology Holdings Inc., a clinical-stage biotechnology company, has announced the initiation of a Phase 1 clinical trial for ALX2004, an epidermal growth factor receptor (EGFR) antibody-drug conjugate $(ADC)$ aimed at treating EGFR-expressing solid tumors. The trial marks the first in-human study of ALX2004 and involves an open-label, multicenter approach. It includes a Phase 1a dose escalation portion focusing on patients with advanced or metastatic non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and colorectal cancer. The trial will subsequently proceed to a dose exploration and expansion phase. Initial safety data from the study is expected to be available in the first half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9514531-en) on August 19, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。